Colorectal cancer (CRC) is among the most prevalent and deadly cancers globally, particularly in China.
Treatment challenges remain in advanced and metastatic cases, especially in third- and fourth-line settings.
The combination of targeted therapies with immune checkpoint inhibitors (ICIs) has shown potential in addressing the limitations of single-agent treatments.
